Cytoskeletal changes during cellular response of the A549 lung cancer cells to continuous cisplatin treatment

Cell Biology International

Volumn 34, Issue 2, 2010, Pages 197-211

  Szczepański, Mariusz Andrzej ^a   Grzanka, Alina ^a   Litwiniec, Anna ^a   Gackowska, Lidia ^b   Kubiszewska, Izabela ^b   Grzanka, Dariusz ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

A549; Cell death; Cisplatin; Cytoskeleton; Microfilament; Microtubule

Indexed keywords

BETA TUBULIN; CISPLATIN; F ACTIN; ACTIN; ANTINEOPLASTIC AGENT; LIPOCORTIN 5; TUBULIN;

ACTIN POLYMERIZATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DRUG ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MICROTUBULE ASSEMBLY; DRUG EFFECT; LUNG TUMOR; METABOLISM; NECROSIS; TUMOR CELL LINE; ULTRASTRUCTURE;

ACTINS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CISPLATIN; CYTOSKELETON; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; NECROSIS; TUBULIN;

EID: 77955286012     PISSN: 10656995     EISSN: 10958355     Source Type: Journal    
DOI: 10.1042/CBI20090035     Document Type: Article

References (82)

1. Aggarwal SK, Sodhi A. Cytotoxic effects of cis-dichlorodiammineplatinum(II) on the mammalian cells in vitro: a fine structural study. Cytobiologie 1973;7:366-74.
2. Aggarwal SK. Fine structural studies using platinum coordination complexes, J Clin Hematol Oncol 1977;7;760-79.
3. Aggarwal SK. Inhibition of cytokinesis in mammalian cells by cisdichlorodiammine-platinum(II). Cytobiologie 1974;8:395-402.
4. Allingham JS, Klenchin VA, Rayment I. Actin-targeting natural products: structures, properties and mechanisms of action. Cell Mol Life Sci 2006;63(18):2119-34.
5. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 2008;122(8):1810-9.
6. Attard G, Greystoke A, Kaye S, De Bono J. Update on tubulin-binding agents. Pathol Biol (Paris) 2006;54(2):72-84.
7. Bell PB, Safiejko-Mroczka B. Improved methods for preserving macromolecular structures and visualizing them by fluorescence and scanning electron microscopy. Scanning Microsc 1995;9:843-60.
8. Bragado P, Armesilla A, Silva A, Porras A. Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation. Apoptosis 2007;12:1733-42.
9. Bubb MR, Senderowicz AM, Sausville EA, Duncan KL, Korn, ED. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem 1994;269:14869-71.
10. Bursch W, Hochegger K, Török L, Marian B, Ellinger A, Hermann RS. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 2000;113:1189-98.
11. Carter CA, Chen C, Brink C, Vincent P, Maxuitenko YY, Gilbert KS, Waud WR, Zhang X. Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother Pharmacol 2007;59(2):183-95.
12. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007;7(1):3-18.
13. Chen YL, Lin SZ, Chang JY, Cheng YL, Tsai NM, Chen SP, Chang WL, Harn HJ. In vitro and in vivo studies of a novel potential anticancer agent of isochaihulactone on human lung cancer A549 cells. Biochem Pharmacol 2006;72(3):308-19.
14. Dimri GP. What has senescence got to do with cancer? Cancer Cell 2005;7(6):505-12.
15. Dunkern TR, Fritz G, Kaina B. Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair. Mutation Research 2001;486:249-58.
16. The mechanism of action of cisplatin: from adducts to apoptosis
17. Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol 2001;48:141-4.
18. Evans RM, Simpkins H. Cisplatin induced intermediate filament reorganization and altered mitochondrial function in 3T3 cells and drug-sensitive and -resistant Walker 256 cells. Exp Cell Res 1998;245(1):69-78.
19. Finger EC, Turley RS, Dong M, How T, Fields TA, Blobe GC. TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. Carcinogenesis 2008;29(3):528-35.
20. Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998;243(2):359-66.
21. Fuertes MA, Alonso C, Perez JM. Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003a;103(3):645-62.
22. Fuertes MA, Castilla J, Alonso C, Perez JM. Cisplatin biochemical mechanisms of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003b;10:257-66.
23. Giganti A, Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res 2003;5:511-25.
24. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Molecular Pharmacology 2001;59:657-63.
25. González-Polo RA, Boya P, Pauleau A-L, Jalil A, Larochette N, Souquòre S, Eskelinen E-L, Pierron G, Saftig P, Kroemer G. The apoptosis/autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005;118:3091-102.
26. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene 2004;23:2891-906.
27. Green KJ, Goldman RD. The effects of taxol on cytoskeletal components in cultured fibroblasts and epithelial cells. Cell Motil 1983;3(4):283-305.
28. Grzanka A, Grzanka D, Orlikowska M. Cytoskeletal reorganization during process of apoptosis induced by cytostatic drugs in K-562 and HL-60 leukemia cell lines. Biochem Pharmacol 2003;66(8):1611-7.
29. Grzanka A, Izdebska M, Litwiniec A, Grzanka D, Safiejko-Mroczka B. Actin filament reorganization in HL-60 leukemia cell line after treatment with G-CSF and GM-CSF. Folia Histochem Cytobiol 2007;45(3):191-7.
30. Grzanka A. Actin distribution patterns in HL-60 leukemia cells treated with etoposide. Acta Histochem 2001;103(4):453-64.
31. Grzanka D, Domaniewski J, Grzanka A, Zuryn A. Ultraviolet radiation (UV) induces reorganization of actin cytoskeleton in CHOAA8 cells. Neoplasma 2006;53(4):328-32.
32. Grzanka D, Domaniewski J, Grzanka A. Actin reorganization in Chinese hamster ovary (CHOAA8) cells induced by doxorubicin. Neoplasma 2005;52(1): 46-51.
33. Grzanka D, Stepien A, Grzanka A, Gackowska L, Helmin-Basa A, Szczepanski MA. Hyperthermia-induced reorganization of microtubules and microfilaments and cell killing in CHO AA8 cell line. Neoplasma 2008;55(5):409-15.
34. Hayot C, Debeir O, Van Ham P, Van Damme M, Kiss R, Decaestecker C. Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol 2006;211(1):30-40.
35. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin2Dna adducts. Chem Rev 1999;99(9):2467-98.
36. Jiang M, Yi X, Hsu S, Wang C-Y, Dong Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 2004;287: F1140-7.
37. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. CMLS, Cell Mol Life Sci 2000;57:1229-35.
38. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26(4): 239-57.
39. Kopf-Maier P, Muhlhausen SK. Changes in the cytoskeleton pattern of tumor cells by cisplatin in vitro. Chem Biol Interact 1992;82(3):295-316.
40. Kruidering M, van de Water B, Zhan Y, Baelde JJ, Heer E, Mulder GJ, Stevens JL, Nagelkerke JF. Cisplatin effects on F-actin and matrix proteins precede renal tubular cell detachment and apoptosis in vitro. Cell Death Differ 1998;5(7):601-14.
41. Ku NO, Zhou X, Toivola DM, Omary MB. The cytoskeleton of digestive epithelia in health and disease. Am J Physiol Gastrointest Liver Physiol 1999;277(6):G1108-37.
42. Kulms D, Düβmann H, Pöppelmann B, Ständer S, Schwarz A, Schwarz T. Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/APO-1). Cell Death and Differentiation 2002;9:598-608.
43. Lieber M, Smith B, Szakal A, Nelson-Rees W and Todaro G. A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells. Int J Cancer 1976;17:62-70.
44. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more. Int J Biochem Cell Biol 2004;36:2405-19.
45. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100-6.
46. Martin DN, Baehrecke EH. Caspases function in autophagic programmed cell death in Drosophila. Development 2003;131:275-84.
47. Montero EI, Perez JM, Schwartz A, Fuertes MA, Malinge JM, Alonso C, Leng M, Navarro-Ranninger C. Apoptosis induction and DNA interstrand cross-link formation by cytotoxic trans-[PtCl2(NH(CH3)2)(NHCH(CH3)2): cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes. Chembiochem 2002;3(1):61-7.
48. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14(22):7167-72.
49. Muller LJ, Gerritsen van der Hoop R, Moorer-van Delft CM, Gispen WH, Roubos EW. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons. Cancer Res 1990;50(8):2437-42.
50. Ndozangue-Touriguine O, Hamelin J, Breard J. Cytoskeleton and apoptosis. Biochem Pharmacol 2008;76(1):11-8.
51. Noda S, Yoshimura S, Sawada M, Naganawa T, Iwama T. Role of ceramice during cisplatin-induced apoptosis in C6 glioma cells. Journal of Neuro-Oncology 2001;52:11-21.
52. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004;4(8):592-603.
53. Paleari L, Catassi A, Ciarlo M, Cavalieri Z, Bruzzo C, Servent D, Cesario A, Chessa L, Cilli M, Piccardi F, Granone P, Russo P. Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation. Cell Prolif 2008;41(6):936-59.
54. Pasquier E, Kavallaris M. Microtubules: a dynamic target in cancer therapy. IUBMB Life 2008;60(3):165-70.
55. Perez JM, Montero EI, Gonzalez AM, Alvarez-Valdes A, Alonso C, Navarro-Ranninger C. Apoptosis induction and inhibition of H-ras overexpression by novel trans-[PtCl2(isopropylamine)(amine)] complexes. J Inorg Biochem. 1999;77(1-2):37-42.
56. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998;34:1535-44.
57. Periyasamy-Thandavan S, Jiang M, Wei Q, Smith R, Yin XM, Dong Z. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 2008;74(5):631-40.
58. Peyrot V, Briand C, Crevat A, Braguer D, Chauvet-Monges AM, Sari JC. Action of hydrolyzed cisplatin and some analogs on microtubule protein polymerization in vitro. Cancer Treat Rep 1983;67(7-8): 641-6.
59. Peyrot V, Briand C, Momburg R, Sari JC. In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammineplatinum(II). Biochem Pharmacol 1986;35(3):371-5.
60. Pollard TD. The cytoskeleton, cellular motility and the reductionist agenda. Nature 2003;422(6933):741-5.
61. Pyo JS, Ju HK, Park JH, Kwon SW. Determination of volatile biomarkers for apoptosis and necrosis by solid-phase microextraction - gas chromatography/mass spectrometry: A pharmacometabolomic approach to cisplatin's cytotoxicity to human lung cancer cell lines. Journal of Chromatography B 2008;876:170-4.
62. Rao J, Li N. Microfilament actin remodeling as a potential target for cancer drug development. Curr Cancer Drug Targets 2004;4(4):345-54.
63. Reedijk J. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 1999;99(9):2499-510.
64. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006;11:342-57.
65. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends in Molecular Medicine 2006;12:440-50.
66. Rosenberg B, van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9.
67. Rosenberg B. Platinum complexes for the treatment of cancer: why the search goes on. In: Lippert B, editor. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug. Basel, Switzerland: Wiley-VCH; 1999. p. 3-27.
68. Safiejko-Mroczka B, Bell PB. Distribution of cytoskeletal proteins in neomycin-induced protrusions of human fibroblasts. Exp Cell Res 1998;242:495-514.
69. Saraste A, Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 2000;45(3):528-37.
70. Segal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995;218(1):201-12.
71. Spector I, Braet F, Shochet NR, Bubb MR. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech 1999;47(1):18-37.
72. Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 2008;14(4):1266-73.
73. Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, Schittulli F, Zito F, Kavallaris M, Paradiso A. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int J Cancer 2007;120(10):2078-85.
74. Tsujimoto Y. Apoptosis and necrosis: intracellular ATP levels as a determinant for cell death modes. Cell Death and Differentiation 1997;4:429-34.
75. Tulub AA, Stefanov VE. Cisplatin stops tubulin assembly into microtubules. A new insight into the mechanism of antitumor activity of platinum complexes. Int J Biol Macromol 2001;28:191-8.
76. Yang C, Kaushal V, Shah SV, Kaushal GP. Autophagy is associated with apoptosis in cisplatin injury to renal tubular epithelial cells. Am J Physiol Renal Physiol 2008;294(4):F777-87.
77. Zakovska A, Novakova O, Balcarona Z, Blerbach U, Farrel NV, Brabec V. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)]. Eur J Biochem 1998;254(3):547-57.
78. Zeidan YH, Jenkins RW, Hannun YA. Remodeling of the cellular cytoskeleton by the acid sphingomyelinase/ceramide pathway. J Cell Biol 2008;181:335-50.
79. Zeng HH, Lu JF, Wang K. The effect of cisplatin and transplatin on the conformation and association of F-actin. Cell Biol Int 1995;19(6):491-7.
80. Zeng HH, Wang B, Wang K. Thermodynamic studies on the effects of cisplatin or its analog complexes on actin polymerization. Thermochimica Acta 2001;373:1-5.
81. Zeng HH, Wang K, Wang B, Zhang Y. Studies on the thermokinetic characterisation of actin polymerization and the effect of cisplatin. Int J Biol Macromol 1996;18(3):161-6.
82. Zeng HH, Xu ZH, Wang K. FT-Raman studies on the transformation of G-actin to F-actin, the binding of cisplatin and transplatin to F-actin and the effects of the conformation of F-actin. Int J Biol Macromol 1997;20(2):107-13.